Repositorio Dspace

Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

Mostrar el registro sencillo del ítem

dc.contributor.author Martínez-Sanz, Javier
dc.contributor.author Díaz-alvarez, Jorge
dc.contributor.author Rosas, Marta
dc.contributor.author Ron, Raquel
dc.contributor.author Iribarren, José-Antonio
dc.contributor.author Bernal-Morell, Enrique
dc.contributor.author Gutiérrez, Félix
dc.contributor.author Sancho, Andres-Ruiz
dc.contributor.author Cabello, Noemi
dc.contributor.author Olalla, Julián
dc.contributor.author Moreno, Santiago
dc.contributor.author Serrano-Villar, Sergio
dc.date.accessioned 2025-11-19T12:39:38Z
dc.date.available 2025-11-19T12:39:38Z
dc.date.issued 2023-09
dc.identifier.issn 2352-3964
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21161
dc.description.abstract BACKGROUND: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. METHODS: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events. FINDINGS: The study included 4625 participants, 83% male, of whom 200 (4.3%) experienced an SNAE during the follow-up period. A CD4/CD8 ratio <0.3 predicted an increased risk of SNAEs during the next five years (OR 1.63, 95% CI 1.03-2.58). The effect was stronger at a CD4/CD8 ratio cut-off of <0.2 (OR 3.09, 95% CI 1.57-6.07). Additionally, low CD4 count at cut-offs of <500 cells/?L predicted an increased risk of clinical events. Among participants with a CD4 count ?500 cells/?L, a CD8 count ?1500 cells/?L or a CD4/CD8 ratio <0.4 predicted increased SNAE risk. INTERPRETATION: Our results support the use of the CD4/CD8 ratio and CD8 count as predictors of clinical progression. Patients with CD4/CD8 ratio <0.3 or CD8 count ?1500/?L, regardless of their CD4 count, may benefit from closer monitoring and targeted preventive interventions. FUNDING: This work was supported by CIBER (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU; by the Spanish AIDS Research Network (RIS) RD16/0025/0001 project as part of the Plan Nacional R + D + I, and cofinanced by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER), ISCIII projects PI18/00154, PI21/00141, and ERDF, "A way to make Europe", ICI20/00058.
dc.language.iso eng
dc.publisher ELSEVIER
dc.rights Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ *
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Female
dc.subject.mesh CD4-CD8 Ratio
dc.subject.mesh Acquired Immunodeficiency Syndrome
dc.subject.mesh CD4 Lymphocyte Count
dc.subject.mesh Europe
dc.subject.mesh CD8-Positive T-Lymphocytes
dc.title Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 37639938
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S2352396423003390
dc.identifier.doi 10.1016/j.ebiom.2023.104773
dc.journal.title Ebiomedicine


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta